Nov 12, 2019 / 05:00PM GMT
Operator
Greetings. Welcome to KOL Call on DUR-928 Phase IIa Alcoholic Hepatitis Study Results, hosted by DURECT. (Operator Instructions) As a reminder, this call is being recorded.
I'll now turn the conference over to Jim Brown, President and CEO of DURECT. Mr. Brown, you may now begin.
James E. Brown - DURECT Corporation - Co-Founder, CEO, President & Director
Thank you. Well, hello, everyone, and welcome to our webcast and the DUR-928 that we're sending here from The Liver Meeting, which is just wrapping up here in Boston. Today, we announced positive results from our Phase IIa clinical trial of DUR-928 in alcoholic hepatitis patients. These results were given in a late-breaking presentation at the meeting this morning by Dr. Tarek Hassanein. Additionally, these studies' results were selected for inclusion in the Best of The Liver Meeting summary slide presentation in the alcoholic-related liver disease category. They were also summarized in the press release that can be found on our website, along with a copy of the slides that Dr. Hassanein and I will
DURECT Corporation - Special Call Transcript
Nov 12, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers